Yonhap Infomax NewsD&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288
D&D Pharmatech in Talks for Technology Transfer of MASH Therapy Candidate DD01
D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.